OS Therapies (NYSEAMERICAN:OSTX) Upgraded by Roth Capital to “Strong-Buy” Rating

Roth Capital upgraded shares of OS Therapies (NYSEAMERICAN:OSTX) to a strong-buy rating in a report released on Thursday,Zacks.com reports.

Other research analysts have also recently issued reports about the stock. D. Boral Capital reissued a “buy” rating and issued a $20.00 price objective on shares of OS Therapies in a research note on Thursday, April 30th. Zacks Research upgraded OS Therapies from a “strong sell” rating to a “hold” rating in a research note on Thursday, June 4th. Finally, Lake Street Capital reduced their target price on OS Therapies from $14.00 to $13.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $13.33.

OS Therapies Stock Up 17.8%

OSTX stock opened at $1.72 on Thursday. OS Therapies has a 12 month low of $1.15 and a 12 month high of $2.57. The firm has a market cap of $76.61 million, a P/E ratio of -1.59 and a beta of -0.83. The company’s 50-day moving average price is $1.79 and its two-hundred day moving average price is $1.55.

OS Therapies (NYSEAMERICAN:OSTX) last issued its earnings results on Monday, May 18th. The company reported ($0.27) EPS for the quarter. Equities analysts predict that OS Therapies will post -0.84 EPS for the current year.

Institutional Investors Weigh In On OS Therapies

Several hedge funds and other institutional investors have recently made changes to their positions in OSTX. Susquehanna International Group LLP acquired a new position in OS Therapies during the 3rd quarter worth approximately $29,000. Jane Street Group LLC acquired a new stake in OS Therapies in the fourth quarter valued at approximately $39,000. Mercer Global Advisors Inc. ADV bought a new stake in shares of OS Therapies during the third quarter worth $40,000. Bridgeway Capital Management LLC bought a new stake in shares of OS Therapies during the second quarter worth $47,000. Finally, XTX Topco Ltd acquired a new position in shares of OS Therapies during the second quarter worth $63,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.